Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
John Kuruvilla(Princess Margaret Cancer Centre), Mansoor Raza Mirza(C4 Therapeutics (United States)), Martin Gutierrez(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health), Bijal Shah(Boston College), Jean‐Richard Saint‐Martin(Roche (Switzerland)), Peter de Nully Brown(Copenhagen University Hospital), Gregory R. Pond(Juravinski Hospital), John S. McCartney(Tongji University), Michael R. Savona(Vanderbilt University), Boris Klebanov(Karyopharm Therapeutics (United States)), Sharon Shacham(Roche (Switzerland)), Ramiro Garzon(Unknown), Yosef Landesman(Karyopharm Therapeutics (United States)), Matthew S. Davids(Dana-Farber Cancer Institute), Morten Mau‐Sørensen(Rigshospitalet), Richard M. Stone(Dana-Farber Cancer Institute), Amit M. Oza(Ontario Institute for Cancer Research), Rachid Baz(Moffitt Cancer Center), Tami Rashal(Roche (Switzerland)), Nashat Gabrail(Gabrail Cancer Center), John C. Byrd(The Ohio State University), Cindy Y. F. Yau(Ozmosis Research (Canada)), Michael Kauffman(Roche (Switzerland)), Dilara McCauley(Karyopharm Therapeutics (United States))
Cited by 30
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k